 Clinical Trials as Topic
"Clinical Trials as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
| Descriptor ID |
D002986
|
| MeSH Number(s) |
E05.318.760.535 E05.337.250 N05.715.360.775.235 N06.850.520.450.535
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials as Topic".
This graph shows the total number of publications written about "Clinical Trials as Topic" by people in UAMS Profiles by year, and whether "Clinical Trials as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 0 | 1 | 1 | | 2024 | 4 | 8 | 12 | | 2023 | 1 | 6 | 7 | | 2022 | 3 | 5 | 8 | | 2021 | 3 | 8 | 11 | | 2020 | 9 | 14 | 23 | | 2019 | 2 | 7 | 9 | | 2018 | 6 | 6 | 12 | | 2017 | 4 | 5 | 9 | | 2016 | 5 | 2 | 7 | | 2015 | 4 | 8 | 12 | | 2014 | 3 | 14 | 17 | | 2013 | 3 | 11 | 14 | | 2012 | 3 | 8 | 11 | | 2011 | 8 | 12 | 20 | | 2010 | 11 | 20 | 31 | | 2009 | 7 | 12 | 19 | | 2008 | 8 | 13 | 21 | | 2007 | 6 | 11 | 17 | | 2006 | 6 | 11 | 17 | | 2005 | 5 | 11 | 16 | | 2004 | 1 | 9 | 10 | | 2003 | 2 | 6 | 8 | | 2002 | 3 | 10 | 13 | | 2001 | 1 | 2 | 3 | | 2000 | 0 | 4 | 4 | | 1998 | 0 | 1 | 1 | | 1997 | 1 | 1 | 2 | | 1996 | 0 | 2 | 2 | | 1995 | 0 | 4 | 4 | | 1994 | 0 | 2 | 2 | | 1993 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 1991 | 2 | 1 | 3 | | 1990 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials as Topic" by people in Profiles over the past ten years.
-
Kakkilaya A, Trando A, Cliff ERS, Mian H, Al Hadidi S, Aziz M, Goodman AM, Jeong AR, Smith WL, Kelkar AH, Russler-Germain DA, Mehra N, Chakraborty R, Gertz MA, Mohyuddin GR. Evaluating early intervention in smoldering myeloma clinical trials: a systematic review. Oncologist. 2025 Feb 06; 30(2).
-
Kumar A, Owen JR, Sloat NT, Maynard E, Hill VM, Hubbard CB, McKinney MS, Sutton LM, McCall SJ, Datto MB, Moyer AN, Caughey BA, Strickler JH, Ramaker RC. Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United States. Curr Oncol. 2024 Nov 16; 31(11):7244-7257.
-
Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P, Method M, Wang Y, Coleman RL, Birrer M, Matulonis UA. Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. Gynecol Oncol. 2024 Dec; 191:249-258.
-
Knowles JK, Warren AEL, Mohamed IS, Stafstrom CE, Koh HY, Samanta D, Shellhaas RA, Gupta G, Dixon-Salazar T, Tran L, Bhatia S, McCabe JM, Patel AD, Grinspan ZM. Clinical trials for Lennox-Gastaut syndrome: Challenges and priorities. Ann Clin Transl Neurol. 2024 Nov; 11(11):2818-2835.
-
Abadi E, Barufaldi B, Lago M, Badal A, Mello-Thoms C, Bottenus N, Wangerin KA, Goldburgh M, Tarbox L, Beaucage-Gauvreau E, Frangi AF, Maidment A, Kinahan PE, Bosmans H, Samei E. Toward widespread use of virtual trials in medical imaging innovation and regulatory science. Med Phys. 2024 Dec; 51(12):9394-9404.
-
Pawlyn C, Schjesvold FH, Cairns DA, Wei LJ, Davies F, Nadeem O, Abdulhaq H, Mateos MV, Laubach J, Weisel K, Ludwig H, Rajkumar SV, Sonneveld P, Jackson G, Morgan G, Richardson PG. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer J. 2024 08 12; 14(1):134.
-
Curtis KK, Fakult NJ, Strunck JL, Aasi SZ, Ahn CS, Alam M, Bar AA, Behshad R, Bichakjian CK, Bolotin D, Boone SL, Bordeaux JS, Brewer JD, Carr DR, Carucci JA, Castillo JR, Christensen SR, Clark MA, Collins LK, Demer AM, Eisen DB, Feng H, Firoz BF, Grekin RC, Hirshburg JM, Holmes TE, Huang CC, Jennings TA, Jiang SIB, Konda S, Leitenberger JJ, Lewin JM, Maher IA, Ng E, Orengo IF, Samie FH, Saylor DK, Sharon VR, Soleymani T, Swetter SM, Tate JA, Van Beek MJ, Vidal NY, Vij A, Wysong A, Xu YG, Carroll BT, Yu WY. Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study. J Natl Compr Canc Netw. 2024 07 30; 22(8).
-
Waisbren SE, Christ SE, Bilder DA, Bjoraker KJ, Bolton S, Chamberlin S, Grant ML, Janzen DM, Katz R, Lubliner E, Martin A, McQueen K, Moshkovich O, Nguyen-Driver M, Shim S, Stefanatos AK, Wilkening G, Harding C. Neurocognitive assessment platform for clinical trials in PKU: White paper developed by the NPKUA neurocognitive workgroup. Mol Genet Metab. 2024 Sep-Oct; 143(1-2):108555.
-
Gowrishankar S, Smith ME, Creber N, Muzaffar J, Borsetto D. Immunosuppression in stem cell clinical trials of neural and retinal cell types: A systematic review. PLoS One. 2024; 19(7):e0304073.
-
Ghobrial IM, Gormley N, Kumar SK, Mateos MV, Bergsagel PL, Chesi M, Dhodapkar MV, Dispenzieri A, Fonseca R, Getz G, Kastritis E, Kristinsson SY, Martinez-Climent JA, Manier S, Marinac CR, Maura F, Morgan GJ, Davies FE, Nadeem O, Nuvolone M, Paiva B, O'Donnell E, Prosper F, Shah UA, Sklavenitis-Pistofidis R, Sperling AS, Vassiliou GS, Munshi NC, Castle PE, Anderson KC, San Miguel JF. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma. Blood Cancer Discov. 2024 May 01; 5(3):146-152.
-
Baum ML, Widge AS, Carpenter LL, McDonald WM, Cohen BM, Nemeroff CB. Pharmacogenomic Clinical Support Tools for the Treatment of Depression. Am J Psychiatry. 2024 Jul 01; 181(7):591-607.
-
Fortney JC, Curran GM, Lyon AR, Check DK, Flum DR. Similarities and Differences Between Pragmatic Trials and Hybrid Effectiveness-Implementation Trials. J Gen Intern Med. 2024 Jul; 39(9):1735-1743.
-
Al Hadidi S. Clinical trials of T-cell re-directing therapy in plasma cell precursor conditions. Eur J Cancer. 2024 May; 203:114045.
-
Newman H, Li Y, Huang YV, Elgarten CW, Myers RM, Ruiz J, Zheng DJ, Leahy AB, Aftandilian C, Arnold SD, Bona K, Gramatges MM, Heneghan MB, Maloney KW, Modi AJ, Mody RJ, Morgan E, Rubnitz J, Winick N, Wilkes JJ, Seif AE, Fisher BT, Aplenc R, Getz KD. Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research. Cancer Med. 2024 Apr; 13(7):e6966.
-
Li H, Mayr NA, Griffin RJ, Zhang H, Pokhrel D, Grams M, Penagaricano J, Chang S, Spraker MB, Kavanaugh J, Lin L, Sheikh K, Mossahebi S, Simone CB, Roberge D, Snider JW, Sabouri P, Molineu A, Xiao Y, Benedict SH. Overview and Recommendations for Prospective Multi-institutional Spatially Fractionated Radiation Therapy Clinical Trials. Int J Radiat Oncol Biol Phys. 2024 Jul 01; 119(3):737-749.
-
Mahle WT, Keesari R, Trachtenberg F, Newburger JW, Lim H, Edelson J, Jeewa A, Lal A, Kindel SJ, Burns KM, Lang S, Bainton J, Carboni M, Villa CR, Richmond M, Henderson H, Menteer J, Pizarro C, Goldberg CS. School age and adolescent heart failure following the Norwood procedure. J Heart Lung Transplant. 2024 03; 43(3):453-460.
-
FitzGerald TJ, Bishop-Jodoin M, Laurie F, Iandoli M, Smith K, Ulin K, Ding L, Moni J, Cicchetti MG, Knopp M, Kry S, Xiao Y, Rosen M, Prior F, Saltz J, Michalski J. The Importance of Quality Assurance in Radiation Oncology Clinical Trials. Semin Radiat Oncol. 2023 10; 33(4):395-406.
-
Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, Fu AZ, Lafeuille MH, Thompson-Leduc P, Khare V, Reitan J, Milkovich G, Kaila S, Davies F, Usmani SZ. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study. Clin Lymphoma Myeloma Leuk. 2024 01; 24(1):55-63.
-
Young BE, Goodmann DR, Hamlin E, Tabaczyk O, Dunn LB, Mu?oz RF, Leykin Y. Is it worth it? Greater risk aversion with lower life satisfaction among depressed individuals. Psychol Health Med. 2024 Apr; 29(4):732-742.
-
Matthew-Onabanjo AN, Nortey G, Matulewicz RS, Basak R, Culton DA, Weaver KN, Gallagher KK, Tan HJ, Rose TL, Milowsky M, Bjurlin MA. Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot. Curr Probl Cancer. 2023 06; 47(3):100958.
-
Li CMY, Tomita Y, Dhakal B, Li R, Li J, Drew P, Price T, Smith E, Maddern GJ, Fenix KA. Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis. J Immunother Cancer. 2023 04; 11(4).
-
Asher S, Kazantzi A, Dekaj F, Steventon L, Khatun A, Ainley L, McMillan A, Rabin N, Wechalekar A, Sive J, Kyriakou C, Papanikolaou X, Xu K, Mahmood S, Wisniowski B, Lee L, Yong K, Popat R. Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma. Haematologica. 2022 12 01; 107(12):2961-2965.
-
Kanchan K, Shankar G, Huffaker MF, Bahnson HT, Chinthrajah RS, Sanda S, Manohar M, Ling H, Paschall JE, Toit GD, Ruczinski I, Togias A, Lack G, Nadeau KC, Jones SM, Nepom GT, Mathias RA. HLA-associated outcomes in peanut oral immunotherapy trials identify mechanistic and clinical determinants of therapeutic success. Front Immunol. 2022; 13:941839.
-
Pesek RD, Gupta SK. Is clinical trial data showing positive progress for the treatment of eosinophilic esophagitis? Expert Opin Emerg Drugs. 2022 09; 27(3):225-227.
-
Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Tricot G, van Rhee F, Al Hadidi S. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA Netw Open. 2022 08 01; 5(8):e2228877.
-
Holstein SA, Asimakopoulos F, Azab AK, Bianchi G, Bhutani M, Crews LA, Cupedo T, Giles H, Gooding S, Hillengass J, John L, Kaiser S, Lee L, Maclachlan K, Pasquini MC, Pichiorri F, Shah N, Shokeen M, Shy BR, Smith EL, Verona R, Usmani SZ, McCarthy PL. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma. Transplant Cell Ther. 2022 08; 28(8):446-454.
-
Lin F, Pa J, Karim R, Hodis HN, Han SD, Henderson VW, St John JA, Mack WJ. Subclinical carotid artery atherosclerosis and cognitive function in older adults. Alzheimers Res Ther. 2022 05 07; 14(1):63.
-
Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA Netw Open. 2022 04 01; 5(4):e228161.
-
Garg S, Rizvi A, Wee D, Sreenivasan A, Suchman K, Thomas SL, Inamdar S, Trindade AJ. Gastroenterology Clinical Trials Transparency: An Analysis of Publication Rates From the ClinicalTrials.gov Database. Am J Gastroenterol. 2022 01 01; 117(1):180-183.
-
Al Hadidi S. The Use of Modified Surrogate End Points in Cancer Clinical Trials. Cancer Invest. 2022 01; 40(1):14-16.
-
Liles DK, Shah NR, Scullin B, Gordeuk VR, Smith WR, Kanter J, Achebe MM, Boccia R, Crary SE, Kraft WK, Archer N, Cataldo V, Hardesty BM, Idowu M, Desai PC, Ikeda A, Puthenveetil G, Hassell KL, Sarnaik S, Kutlar A. Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study. Br J Haematol. 2021 11; 195(4):e150-e153.
-
Commiskey P, Armstrong AW, Coker TR, Dorsey ER, Fortney JC, Gaines KJ, Gibbons BM, Nguyen HQ, Singla DR, Szigethy E, Krupinski EA. A Blueprint for the Conduct of Large, Multisite Trials in Telemedicine. J Med Internet Res. 2021 09 20; 23(9):e29511.
-
Ghafuri DL, Covert Greene B, Musa B, Gambo A, Sani A, Abdullahi S, Wudil BJ, Bello-Manga H, Gambo S, Ghafuri M, Cassell H, Neville K, Kirkham F, Kassim AA, Aliyu MH, DeBaun MR, Jordan LC. Capacity Building for Primary Stroke Prevention Teams in Children Living With Sickle Cell Anemia in Africa. Pediatr Neurol. 2021 12; 125:9-15.
-
Shaw JL, Semmens E, Okihiro M, Lewis JL, Hirschfeld M, VanWagoner TM, Stephens L, Easa D, Ross JL, Graham N, Watson SE, Szyld EG, Dillard DA, Pyles LA, Darden PM, Carlson JC, Smith PG, McCulloh RJ, Snowden JN, Adeky SH, Singleton R. Best Practices for Conducting Clinical Trials With Indigenous Children in the United States. Am J Public Health. 2021 Sep; 111(9):1645-1653.
-
Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J Med Chem. 2021 08 26; 64(16):11747-11773.
-
Chambers A, Kundranda M, Rao S, Mahmoud F, Niu J. Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors. Curr Oncol Rep. 2021 07 16; 23(9):100.
-
Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021 09; 68(9):e29188.
-
Griffiths JI, Chen J, Cosgrove PA, O'Dea A, Sharma P, Ma C, Trivedi M, Kalinsky K, Wisinski KB, O'Regan R, Makhoul I, Spring LM, Bardia A, Adler FR, Cohen AL, Chang JT, Khan QJ, Bild AH. Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy. Nat Cancer. 2021 06; 2(6):658-671.
-
Kearns GL, van den Anker JN. Adolescents and Drug Development: Commentary on a Dawning Paradigm Shift. J Clin Pharmacol. 2021 06; 61(6):740-743.
-
Richter J, Ramasamy K, Rasche L, Blad? J, Zweegman S, Davies F, Dimopoulos M. Management of patients with difficult-to-treat multiple myeloma. Future Oncol. 2021 Jun; 17(16):2089-2105.
-
Garza MY, Rutherford M, Myneni S, Fenton S, Walden A, Topaloglu U, Eisenstein E, Kumar KR, Zimmerman KO, Rocca M, Gordon GS, Hume S, Wang Z, Zozus M. Evaluating the Coverage of the HL7 ? FHIR ? Standard to Support eSource Data Exchange Implementations for use in Multi-Site Clinical Research Studies. AMIA Annu Symp Proc. 2020; 2020:472-481.
-
Al Hadidi S, Ramos CA. Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies. Leuk Lymphoma. 2021 06; 62(6):1522-1524.
-
Zhou X, Rasche L, Kort?m KM, Danhof S, Hudecek M, Einsele H. Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. Front Immunol. 2020; 11:620312.
-
Price KN, Lyons AB, Hamzavi IH, Hsiao JL, Shi VY. Facilitating Clinical Trials Participation of Low Socioeconomic Status Patients. Dermatology. 2021; 237(5):843-846.
-
Zheutlin AR, Caldwell D, Anstey DE, Conroy MB, Ogedegbe O, Bress AP. Trends in Hypertension Clinical Trials Focused on Interventions Specific for Black Adults: An Analysis of ClinicalTrials.gov. J Am Heart Assoc. 2020 12 15; 9(24):e018512.
-
Borcherding N, Jethava Y, Vikas P. Repurposing Anti-Cancer Drugs for COVID-19 Treatment. Drug Des Devel Ther. 2020; 14:5045-5058.
-
Samanta D. Improving Management of Infantile Spasms by Adopting Implementation Science. Neuropediatrics. 2020 12; 51(6):377-388.
-
Paul B, Atrash S, Bhutani M, Voorhees P, Hamadeh I, Usmani SZ. An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma. Expert Rev Hematol. 2020 08; 13(8):795-802.
-
Annett RD, Chervinskiy S, Chun TH, Cowan K, Foster K, Goodrich N, Hirschfeld M, Hsia DS, Jarvis JD, Kulbeth K, Madden C, Nesmith C, Raissy H, Ross J, Saul JP, Shiramizu B, Smith P, Sullivan JE, Tucker L, Atz AM. IDeA States Pediatric Clinical Trials Network for Underserved and Rural Communities. Pediatrics. 2020 10; 146(4).
-
Walden A, Garvin L, Smerek M, Johnson C. User-centered design principles in the development of clinical research tools. Clin Trials. 2020 12; 17(6):703-711.
-
Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30.
-
He Y, Khan S, Huo Z, Lv D, Zhang X, Liu X, Yuan Y, Hromas R, Xu M, Zheng G, Zhou D. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. J Hematol Oncol. 2020 07 27; 13(1):103.
-
Mahmoodi BK, Tragante V, Kleber ME, Holmes MV, Schmidt AF, McCubrey RO, Howe LJ, Direk K, Allayee H, Baranova EV, Braund PS, Delgado GE, Eriksson N, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Pasterkamp G, Kotti S, Kuukasj?rvi P, Lenzini PA, Levin D, Lyytik?inen LP, Muehlschlegel JD, Nelson CP, Nikus K, Pilbrow AP, Wilson Tang WH, van der Laan SW, van Setten J, Vilmundarson RO, Deanfield J, Deloukas P, Dudbridge F, James S, Mordi IR, Teren A, Bergmeijer TO, Body SC, Bots M, Burkhardt R, Cooper-DeHoff RM, Cresci S, Danchin N, Doughty RN, Grobbee DE, Hagstr?m E, Hazen SL, Held C, Hoefer IE, Hovingh GK, Johnson JA, Kaczor MP, K?h?nen M, Klungel OH, Laurikka JO, Lehtim?ki T, Maitland-van der Zee AH, McPherson R, Palmer CN, Kraaijeveld AO, Pepine CJ, Sanak M, Sattar N, Scholz M, Simon T, Spertus JA, Stewart AFR, Szczeklik W, Thiery J, Visseren FLJ, Waltenberger J, Richards AM, Lang CC, Cameron VA, ?kerblom A, Pare G, M?rz W, Samani NJ, Hingorani AD, Ten Berg JM, Wallentin L, Asselbergs FW, Patel RS. Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. Circulation. 2020 08 11; 142(6):546-555.
-
Lakkaniga NR, Zhang L, Belachew B, Gunaganti N, Frett B, Li HY. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. Eur J Med Chem. 2020 Oct 01; 203:112589.
-
Shah PP, White T, Khalafallah AM, Romo CG, Price C, Mukherjee D. A systematic review of tumor treating fields therapy for high-grade gliomas. J Neurooncol. 2020 Jul; 148(3):433-443.
-
Al Hadidi S, Mims M, Miller-Chism CN, Kamble R. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs. Ann Intern Med. 2020 08 18; 173(4):320-322.
-
Eisenstein EL, Garza MY, Rocca M, Gordon GS, Zozus M. eSource-Enabled vs. Traditional Clinical Trial Data Collection Methods: A Site-Level Economic Analysis. Stud Health Technol Inform. 2020 Jun 16; 270:961-965.
-
Collier EK, Hsiao JL, Shi VY. Conducting clinical trials during the COVID-19 pandemic. J Dermatolog Treat. 2020 Jun; 31(4):330-332.
-
Loflin MJE, Kiluk BD, Huestis MA, Aklin WM, Budney AJ, Carroll KM, D'Souza DC, Dworkin RH, Gray KM, Hasin DS, Lee DC, Le Foll B, Levin FR, Lile JA, Mason BJ, McRae-Clark AL, Montoya I, Peters EN, Ramey T, Turk DC, Vandrey R, Weiss RD, Strain EC. The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug Alcohol Depend. 2020 07 01; 212:107993.
-
Griffin RJ, Ahmed MM, Amendola B, Belyakov O, Bentzen SM, Butterworth KT, Chang S, Coleman CN, Djonov V, Formenti SC, Glatstein E, Guha C, Kalnicki S, Le QT, Loo BW, Mahadevan A, Massaccesi M, Maxim PG, Mohiuddin M, Mohiuddin M, Mayr NA, Obcemea C, Petersson K, Regine W, Roach M, Romanelli P, Simone CB, Snider JW, Spitz DR, Vikram B, Vozenin MC, Abdel-Wahab M, Welsh J, Wu X, Limoli CL. Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 07 15; 107(4):766-778.
-
Collier EK, Hsiao JL, Shi VY, Naik HB. Comprehensive approach to managing hidradenitis suppurativa patients. Int J Dermatol. 2020 Jun; 59(6):744-747.
-
Atrash S, Bano K, Harrison B, Abdallah AO. CAR-T treatment for hematological malignancies. J Investig Med. 2020 06; 68(5):956-964.
-
Hook EW, Newman L, Drusano G, Evans S, Handsfield HH, Jerse AE, Kong FYS, Lee JY, Taylor SN, Deal C. Development of New Antimicrobials for Urogenital Gonorrhea Therapy: Clinical Trial Design Considerations. Clin Infect Dis. 2020 03 17; 70(7):1495-1500.
-
Li Q, He Z, Guo Y, Zhang H, George TJ, Hogan W, Charness N, Bian J. Assessing the Validity of a a priori Patient-Trial Generalizability Score using Real-world Data from a Large Clinical Data Research Network: A Colorectal Cancer Clinical Trial Case Study. AMIA Annu Symp Proc. 2019; 2019:1101-1110.
-
Mason MJ, Schinke C, Eng CLP, Towfic F, Gruber F, Dervan A, White BS, Pratapa A, Guan Y, Chen H, Cui Y, Li B, Yu T, Chaibub Neto E, Mavrommatis K, Ortiz M, Lyzogubov V, Bisht K, Dai HY, Schmitz F, Flynt E, Danziger SA, Ratushny A, Dalton WS, Goldschmidt H, Avet-Loiseau H, Samur M, Hayete B, Sonneveld P, Shain KH, Munshi N, Auclair D, Hose D, Morgan G, Trotter M, Bassett D, Goke J, Walker BA, Thakurta A, Guinney J. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020 07; 34(7):1866-1874.
-
Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020 04; 34(4):985-1005.
-
Tang J, Landes RD. Some t-tests for N-of-1 trials with serial correlation. PLoS One. 2020; 15(2):e0228077.
-
Morgan GJ, Williams L. Antibody-based targeting of BCMA in multiple myeloma. Lancet Oncol. 2020 02; 21(2):186-187.
-
Ho KKHY, Ferruzzi MG, Wightman JD. Potential health benefits of (poly)phenols derived from fruit and 100% fruit juice. Nutr Rev. 2020 02 01; 78(2):145-174.
-
Engelen MPKJ, Jonker R, Thaden JJ, Ten Have GAM, Jeon MS, Dasarathy S, Deutz NEP. Comprehensive metabolic flux analysis to explain skeletal muscle weakness in COPD. Clin Nutr. 2020 10; 39(10):3056-3065.
-
Makhlouf H, Watson MA, Lankes HA, Weil C, Dickler M, Birrer M, Moskaluk C, Ramirez NC, Okby N, Alonsozana E, Barnes M, Goldman EB, Enos R, Lubensky I. Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. Am J Clin Pathol. 2020 01 02; 153(2):149-155.
-
Price KN, Hsiao JL, Shi VY. Race and Ethnicity Gaps in Global Hidradenitis Suppurativa Clinical Trials. Dermatology. 2021; 237(1):97-102.
-
Pesek RD, Gupta SK. Future therapies for eosinophilic gastrointestinal disorders. Ann Allergy Asthma Immunol. 2020 03; 124(3):219-226.
-
Blakely EA, Faddegon B, Tinkle C, Bloch C, Dominello M, Griffin RJ, Joiner MC, Burmeister J. Three discipline collaborative radiation therapy (3DCRT) special debate: The United States needs at least one carbon ion facility. J Appl Clin Med Phys. 2019 Nov; 20(11):6-13.
-
Kim B, Sullivan JL, Ritchie MJ, Connolly SL, Drummond KL, Miller CJ, Greenan MA, Bauer MS. Comparing variations in implementation processes and influences across multiple sites: What works, for whom, and how? Psychiatry Res. 2020 01; 283:112520.
-
Landes SJ, McBain SA, Curran GM. An introduction to effectiveness-implementation hybrid designs. Psychiatry Res. 2019 10; 280:112513.
-
Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. Incidence and Management of Olaratumab Infusion-Related Reactions. J Oncol Pract. 2019 11; 15(11):e925-e933.
-
Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-Drug Conjugate-Based Therapeutics: State of the Science. J Natl Cancer Inst. 2019 Jun 01; 111(6):538-549.
-
Hallberg SJ, Dockter NE, Kushner JA, Athinarayanan SJ. Improving the scientific rigour of nutritional recommendations for adults with type 2 diabetes: A comprehensive review of the American Diabetes Association guideline-recommended eating patterns. Diabetes Obes Metab. 2019 08; 21(8):1769-1779.
-
Randall LM, Birrer MJ, Herzog TJ. Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice. Oncologist. 2019 05; 24(5):576-579.
-
Shakhnovich V, Hornik CP, Kearns GL, Weigel J, Abdel-Rahman SM. How to Conduct Clinical Trials in Children: A Tutorial. Clin Transl Sci. 2019 05; 12(3):218-230.
-
Birrer MJ, Betella I, Martin LP, Moore KN. Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age? Oncologist. 2019 04; 24(4):425-429.
-
Nordo A, Eisenstein EL, Garza M, Hammond WE, Zozus MN. Evaluative Outcomes in Direct Extraction and Use of EHR Data in Clinical Trials. Stud Health Technol Inform. 2019; 257:333-340.
-
Zhang H, He Z, He X, Guo Y, Nelson DR, Modave F, Wu Y, Hogan W, Prosperi M, Bian J. Computable Eligibility Criteria through Ontology-driven Data Access: A Case Study of Hepatitis C Virus Trials. AMIA Annu Symp Proc. 2018; 2018:1601-1610.
-
Goel A, Pothineni NV, Singhal M, Paydak H, Saldeen T, Mehta JL. Fish, Fish Oils and Cardioprotection: Promise or Fish Tale? Int J Mol Sci. 2018 Nov 22; 19(12).
-
Patel KV, Allen R, Burke L, Farrar JT, Gewandter JS, Gilron I, Katz NP, Markman JD, Marshall SF, Resnick M, Rice ASC, Rowbotham MC, Smith SM, Vanhove GF, Wasan AD, Zhang S, Dworkin RH, Turk DC. Evaluation of composite responder outcomes of pain intensity and physical function in neuropathic pain clinical trials: an ACTTION individual patient data analysis. Pain. 2018 Nov; 159(11):2245-2254.
-
Abraham A, Kattoor AJ, Saldeen T, Mehta JL. Vitamin E and its anticancer effects. Crit Rev Food Sci Nutr. 2019; 59(17):2831-2838.
-
van Rhee F, Voorhees P, Dispenzieri A, Foss? A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124.
-
Ghoneum A, Afify H, Salih Z, Kelly M, Said N. Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities. Cancer Med. 2018 10; 7(10):5047-5056.
-
Imig JD. Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. Pharmacol Ther. 2018 12; 192:1-19.
-
He Z, Gonzalez-Izquierdo A, Denaxas S, Sura A, Guo Y, Hogan WR, Shenkman E, Bian J. Comparing and Contrasting A Priori and A Posteriori Generalizability Assessment of Clinical Trials on Type 2 Diabetes Mellitus. AMIA Annu Symp Proc. 2017; 2017:849-858.
-
Lindner MD, Torralba KD, Khan NA. Scientific productivity: An exploratory study of metrics and incentives. PLoS One. 2018; 13(4):e0195321.
-
Snowden J, Darden P, Palumbo P, Saul P, Lee J. The institutional development award states pediatric clinical trials network: building research capacity among the rural and medically underserved. Curr Opin Pediatr. 2018 04; 30(2):297-302.
-
DeCou CR, Comtois KA, Landes SJ. Dialectical Behavior Therapy Is Effective for the Treatment of Suicidal Behavior: A Meta-Analysis. Behav Ther. 2019 01; 50(1):60-72.
-
Pothineni NV, Kattoor AJ, Kovelamudi S, Kenchaiah S. The Current Focus of Heart Failure Clinical Trials. J Card Fail. 2018 May; 24(5):321-329.
-
Torok RD, Li JS, Kannankeril PJ, Atz AM, Bishai R, Bolotin E, Breitenstein S, Chen C, Diacovo T, Feltes T, Furlong P, Hanna M, Graham EM, Hsu D, Ivy DD, Murphy D, Kammerman LA, Kearns G, Lawrence J, Lebeaut B, Li D, Male C, McCrindle B, Mugnier P, Newburger JW, Pearson GD, Peiris V, Percival L, Pina M, Portman R, Shaddy R, Stockbridge NL, Temple R, Hill KD. Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank. J Am Heart Assoc. 2018 02 10; 7(4).
-
Holstein SA, Avet-Loiseau H, Hahn T, Ho CM, Lohr JG, Munshi NC, Paiva B, Pasquini MC, Tario JD, Usmani SZ, Wallace PK, Weisel K, McCarthy PL. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biol Blood Marrow Transplant. 2018 04; 24(4):641-648.
-
Maarouf M, Clark AK, Lee DE, Shi VY. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug; 29(5):441-449.
-
Ward RM, Benjamin DK, Davis JM, Gorman RL, Kauffman R, Kearns GL, Murphy MD, Sherwin CMT. The Need for Pediatric Drug Development. J Pediatr. 2018 01; 192:13-21.
-
Lee DE, Clark AK, Tran KA, Shi VY. New and emerging targeted systemic therapies: a new era for atopic dermatitis. J Dermatolog Treat. 2018 Jun; 29(4):364-374.
-
Bhutani M, Zhang Q, Friend R, Voorhees PM, Druhan LJ, Barlogie B, Sonneveld P, Morgan GJ, Symanowski JT, Avalos BR, Copelan EA, Usmani SZ. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. Lancet Haematol. 2017 Sep; 4(9):e443-e451.
-
Boegemann M, Aydin AM, Bagrodia A, Krabbe LM. Prospects and progress of immunotherapy for bladder cancer. Expert Opin Biol Ther. 2017 11; 17(11):1417-1431.
-
Zozus MN, Lazarov A, Smith LR, Breen TE, Krikorian SL, Zbyszewski PS, Knoll SK, Jendrasek DA, Perrin DC, Zambas DN, Williams TB, Pieper CF. Analysis of professional competencies for the clinical research data management profession: implications for training and professional certification. J Am Med Inform Assoc. 2017 Jul 01; 24(4):737-745.
-
Sardar P, Chatterjee S, Aronow HD, Kundu A, Ramchand P, Mukherjee D, Nairooz R, Gray WA, White CJ, Jaff MR, Rosenfield K, Giri J. Carotid Artery Stenting Versus Endarterectomy for Stroke Prevention: A Meta-Analysis of Clinical Trials. J Am Coll Cardiol. 2017 May 09; 69(18):2266-2275.
-
Phillips C. Physical Activity Modulates Common Neuroplasticity Substrates in Major Depressive and Bipolar Disorder. Neural Plast. 2017; 2017:7014146.
-
Leykin Y, Dunn LB, Mu?oz RF. The effect of depression on the decision to join a clinical trial. J Consult Clin Psychol. 2017 Jul; 85(7):751-756.
-
Bauer SR, Abraham PE, Barletta JF, Brophy GM, Erstad BL, Gonzales JP, Haas CE, MacLaren R, Mueller EW, Olsen KM, Lat I. Development of the Critical Care Pharmacotherapy Trials Network. Am J Health Syst Pharm. 2017 03 01; 74(5):287-293.
-
Sterne JA, Hern?n MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hr?bjartsson A, Kirkham J, J?ni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Sch?nemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12; 355:i4919.
-
Taylor AM, Phillips K, Patel KV, Turk DC, Dworkin RH, Beaton D, Clauw DJ, Gignac MAM, Markman JD, Williams DA, Bujanover S, Burke LB, Carr DB, Choy EH, Conaghan PG, Cowan P, Farrar JT, Freeman R, Gewandter J, Gilron I, Goli V, Gover TD, Haddox JD, Kerns RD, Kopecky EA, Lee DA, Malamut R, Mease P, Rappaport BA, Simon LS, Singh JA, Smith SM, Strand V, Tugwell P, Vanhove GF, Veasley C, Walco GA, Wasan AD, Witter J. Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain. 2016 Sep; 157(9):1836-1850.
-
Dunn LB, Wiley J, Garrett S, Hlubocky F, Daugherty C, Trupin L, Munster P, Dohan D. Interest in initiating an early phase clinical trial: results of a longitudinal study of advanced cancer patients. Psychooncology. 2017 Oct; 26(10):1604-1610.
-
Sarkar S, Raymick J, Imam S. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci. 2016 Jun 08; 17(6).
-
Jones JR, Pawlyn C, Davies FE, Morgan GJ. The safety of pomalidomide for the treatment of multiple myeloma. Expert Opin Drug Saf. 2016; 15(4):535-47.
-
Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis. 2016 Mar; 20(3):290-4.
-
Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Immunotherapy. 2016; 8(3):367-84.
-
Cooper SA, Desjardins PJ, Turk DC, Dworkin RH, Katz NP, Kehlet H, Ballantyne JC, Burke LB, Carragee E, Cowan P, Croll S, Dionne RA, Farrar JT, Gilron I, Gordon DB, Iyengar S, Jay GW, Kalso EA, Kerns RD, McDermott MP, Raja SN, Rappaport BA, Rauschkolb C, Royal MA, Segerdahl M, Stauffer JW, Todd KH, Vanhove GF, Wallace MS, West C, White RE, Wu C. Research design considerations for single-dose analgesic clinical trials in acute pain: IMMPACT recommendations. Pain. 2016 Feb; 157(2):288-301.
-
Steinbach WJ, Lamoth F, Juvvadi PR. Potential Microbiological Effects of Higher Dosing of Echinocandins. Clin Infect Dis. 2015 Dec 01; 61 Suppl 6:S669-77.
-
Elliott JH, Grimshaw J, Altman R, Bero L, Goodman SN, Henry D, Macleod M, Tovey D, Tugwell P, White H, Sim I. Informatics: Make sense of health data. Nature. 2015 Nov 05; 527(7576):31-2.
-
Danhof S, Schreder M, Rasche L, Strifler S, Einsele H, Knop S. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors. Eur J Haematol. 2016 Jul; 97(1):25-32.
-
Henry D, Fitzpatrick T. Liberating the data from clinical trials. BMJ. 2015 Sep 16; 351:h4601.
-
Robson JC, Milman N, Tomasson G, Dawson J, Cronholm PF, Kellom K, Shea J, Ashdown S, Boers M, Boonen A, Casey GC, Farrar JT, Gebhart D, Krischer J, Lanier G, McAlear CA, Peck J, Sreih AG, Tugwell PS, Luqmani RA, Merkel PA. Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process. J Rheumatol. 2015 Nov; 42(11):2204-9.
-
Pothineni NV, Deshmukh A, Padmanabhan D, Kovelamudi S, Patel NJ, Badheka AO, Mulpuru SK, Paydak H, Noseworthy PA. Complication rates of ventricular tachycardia ablation: Comparison of safety outcomes derived from administrative databases and clinical trials. Int J Cardiol. 2015 Dec 15; 201:529-31.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|